Gregory Lesinski: Winship Team Publishes Novel CAR/VIPRa T-Cell Therapy in Science
oncodaily - Gregory Lesinski, Associate Director of Basic Research at Winship Cancer Institute of Emory University, shared on LinkedIn by Sarwish Rafiq, Assistant Professor at the Emory University School of Medicine and […]
AI Summary: Researchers published a novel CAR T‑cell approach exploiting the VIP–VIPR pathway that reprograms cells for superior antitumor activity in preclinical models. The Winship team’s paper reports enhanced tumor killing and durability in laboratory studies, flagging a promising route to improve CAR T efficacy in solid tumors — still very early, but intriguing.
Related Stories
CAR‑T depletes mutant calreticulin cells, offering myelofibrosis hope / 2 months
Dendritic cells build tumour immune hubs sustaining anti-tumour responses / 7 wks
Mass spectrometry platform could cut drug discovery to hours / 2 months
Engineered CAR‑T cells secreting VEGF‑neutralizing scFvs boost solid‑tumor activity / 5 months
Decade-Long Persistence of CD19 CAR‑T Cells in B‑Cell Lymphomas / 23 days
Ten‑year follow‑up shows durable remissions with CD19 CAR‑T therapy / 2 months
CRISPR CD33‑deleted allogeneic transplant shows early AML promise / 3 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Diagnostics, Healthcare, Pfizer, Nutrition and look for the RSS link.
StackHealth Time Machine